1529 Treffer:
151.
A Phase 1b/2a, Multicenter, Open-label Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
NCT Heidelberg » Für Ärzte » Studien » Hämatologische Neoplasien » Multiples Myelom
Datum: 2026-05-09
152.
A Post-authorization Safety Study to Evaluate the Safety of Multiple Myeloma Patients Treated with Ciltacabtagene Autoleucel
NCT Heidelberg » Für Ärzte » Studien » Hämatologische Neoplasien » Multiples Myelom
Datum: 2026-05-09
153.
Randomized, Multicenter, Open-label, Phase 3 Study of Mirvetuximab Soravtansine in Combination With Bevacizumab Versus Bevacizumab Alone as Maintenance Therapy for Patients With FR?-high Recurrent Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or
NCT Heidelberg » Für Ärzte » Studien » Gynäkologische Tumoren/Mammakarzinom » Ovarialkarzinom
Datum: 2026-05-09
154.
An open-label, phase I/II multicenter clinical trial of NECVAX-NEO1 as add-on to first-line neoadjuvant anti-PD-1 monoclonal antibody therapy in patients with triple-negative breast cancer
NCT Heidelberg » Für Ärzte » Studien » Gynäkologische Tumoren/Mammakarzinom » Mammakarzinom
Datum: 2026-05-09
155.
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation - MajesTEC-4
NCT Heidelberg » Für Ärzte » Studien » Hämatologische Neoplasien » Multiples Myelom
Datum: 2026-05-09
156.
Deutsches MPN-Register und Biomaterialbank für BCR-ABL1-negative myeloische NeoplasienDeutsches MPN-Register und Biomaterialbank für BCR-ABL1-negative myeloische Neoplasien
NCT Heidelberg » Für Ärzte » Studien » Hämatologische Neoplasien » Myeloproliferative Erkrankungen
Datum: 2026-05-09
157.
A Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR-T Cell Therapy, Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalido
NCT Heidelberg » Für Ärzte » Studien » Hämatologische Neoplasien » Multiples Myelom
Datum: 2026-05-09
158.
A Phase Ia/Ib First-In-Human Clinical Trial to Evaluate the Safety, Tolerability and Initial Anti-tumor Activity of IMA401, a Bispecific T Cell Engaging Receptor Molecule (TCER®), in Patients With Recurrent and/or Refractory Solid Tumors.
NCT Heidelberg » Für Ärzte » Studien » Kopf-/Hals Tumoren
Datum: 2026-05-09
159.
Multiparametric Imaging-based Intraoperative Navigation for Guidance of Surgical Resection and Postoperative Radiotherapy in Patients With Head-and-neck Tumors - NAVIGATORR
NCT Heidelberg » Für Ärzte » Studien » Kopf-/Hals Tumoren
Datum: 2026-05-09
160.
A prospective, international, multicenter registry of patients undergoing segmental mandibular defects reconstruction (SMDR) after mandibular resection for tumors and drugs-induced osteonecrosis
NCT Heidelberg » Für Ärzte » Studien » Kopf-/Hals Tumoren
Datum: 2026-05-09